115619-00-6

Basic information

• Product Name: 1-ETHYL-4-(4-NITROPHENYL)PIPERAZINE
• Synonyms: 1-ETHYL-4-(4-NITROPHENYL)PIPERAZINE;1-ETHYL-4-(4-NITROPHENYL)PIPERAZINE, 95+%;Piperazine, 1-ethyl-4-(4-nitrophenyl)-
• CAS NO: 115619-00-6
• Molecular Formula: C₁₂H₁₇N₃O₂
• Molecular Weight: 235.28
• Mol File: 115619-00-6.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 381.9±37.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.163±0.06 g/cm3(Predicted)
• PKA: 7.76±0.10(Predicted)
• CAS DataBase Reference: 1-ETHYL-4-(4-NITROPHENYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ETHYL-4-(4-NITROPHENYL)PIPERAZINE(115619-00-6)
• EPA Substance Registry System: 1-ETHYL-4-(4-NITROPHENYL)PIPERAZINE(115619-00-6)

Safety Data

• Hazardous Substances Data: 115619-00-6(Hazardous Substances Data)

Usage

General Description

1-Ethyl-4-(4-nitrophenyl)piperazine is a chemical compound with the molecular formula C14H20N4O2. It belongs to the class of piperazine derivatives and contains a piperazine ring with an ethyl group and a nitrophenyl group attached. 1-ETHYL-4-(4-NITROPHENYL)PIPERAZINE has potential applications in pharmaceutical and research fields due to its structural properties and interactions with biological systems. It is commonly used as an intermediate in the synthesis of various pharmaceutical drugs and may also have potential biological activities that make it of interest for further study. Additionally, it should be handled and used with appropriate safety precautions and under the guidance of a qualified professional due to its potential reactivity and toxicity.

Upstream product

• 5308-25-8 4-ethylpiperazine 
• 100-00-5 4-chlorobenzonitrile 
• 636-98-6 p-nitrobenzene iodide 
• 586-78-7 para-nitrophenyl bromide 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 1313481-14-9 6-chloro-N-(4-(4-ethylpiperazin-1-yl)phenyl)-2-methoxyacridin-9-amine 
• 1580002-67-0 (E)-N-[4-(4-ethylpiperazin-1-yl)phenyl]-3-(4-nitrophenyl)acrylamide 
• 1580002-59-0 (E)-N-[4-(4-ethylpiperazin-1-yl)phenyl]cinnamamide 
• 872511-35-8 of N⁴-(4-(4-ethylpiperazin-1-yl)phenyl)-N⁶-methylpyrimidine-4,6-diamine 
• 115619-01-7 4-(4-ethylpiperazin-1-yl)aniline 
• 1197329-93-3 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1-yl)-phenyl]-amide 
• 1197331-55-7 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [4-(4-ethyl-piperazin-1-yl)-phenyl]-amide 

Relevant articles and documents

Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma

A series of cyano-substituted 2,4-diarylaminopyrimidines was designed and synthesized as potent non-covalent JAK3 inhibitors. Among the derivatives synthesized, 9o (IC50 = 22.86 nM), 9 k (IC50 = 21.58 nM), and 9j (IC50 = 20.66 nM) demonstrated inhibitory potencies against JAK3 similar to the known JAK3 inhibitor tofacitinib (IC50 = 20.10 nM). Moreover, 9o displayed potent anti-proliferative activities against Raji and Ramos cells, with IC50 values of 0.9255 μM and 1.405 μM, respectively. In addition, 9o demonstrated low toxicity in normal HBE (human bronchial epithelial cells, IC50 > 10 μΜ) and L-02 (human liver cells, IC50 = 3.104 μΜ) cells. Analysis of the mode of action by flow cytometry indicated that 9o effectively arrested Raji cells at the G2/M phase. Taken together, these results suggested that 9o might be a promising candidate for development as a potential treatment for B-cell lymphoma.

FGFR INHIBITOR AND APPLICATION THEREOF

An azatricyclic compound (as represented by formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. AA%%%Formula (I).

FUSED PYRIMIDINOPIPERIDINE DERIVATIVE, AND MANUFACTURING METHOD AND APPLICATION THEREOF

The present invention relates to the fused pyrimidine piperidine cyclic derivative represented by the following formula (I) and a pharmaceutically acceptable salt thereof and a process for preparing the same, wherein R1, R2, R3